POZEN –

Chapel Hill, N.C.

Went public 10/11/00 at $15 per share

Filing Range:5.0 million shares @ $14 to $16

Shares Outstanding:26.4 million shares

Underwriters: U.S. Bancorp Piper Jaffray/Prudential Vector Healthcare/Pacific Growth Equities Inc.

Company Counsel: Morgan Lewis & Bockius

Manager Counsel: Ballard Spahr Andrews & Ingersoll

Auditor: Ernst & Young LLP

The Company:

Operates a pharmaceutical development company. Pozen’s initial area of focus is migraines, where it has built a portfolio of four product candidates through a combination of innovation and in-licensing.

Venture Backers:

Canaan Partners

Vector Fund Management LP

Financing Rounds:

Number of Round Amt.

Round # Round Date Stage Investors ($ thousands)

1 12/01/1996 1 Early Stage 6634.0

2 12/01/1997 1 Early Stage 4540.0

3 03/01/1998 1 Expansion 2300.0

4 07/01/1999 2 Later Stage 12450.0

5 08/01/2000 4 Later Stage 29101.0

Financials:

(Data in $ millions)

Y/E

12/31/99

Total Revenues: $0.0

Net Income: -11.3